Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

被引：0
|
作者：
François-Clément Bidard
David Hajage
Thomas Bachelot
Suzette Delaloge
Etienne Brain
Mario Campone
Paul Cottu
Philippe Beuzeboc
Emilie Rolland
Claire Mathiot
Jean-Yves Pierga
机构：
[1] Institut Curie,Department of Medical Oncology
[2] Université Paris Descartes,Department of Biostatistics
[3] Institut Curie,Department of Medical Oncology
[4] Centre Léon Bérard,Department of Medical Oncology
[5] Institut Gustave Roussy,Department of Medical Oncology
[6] Institut Curie,Department of Medical Oncology
[7] Hôpital René Huguenin,Hematology laboratory
[8] Institut de Cancérologie de l'Ouest,undefined
[9] Bd Monod,undefined
[10] Institut Curie,undefined
来源：
Breast Cancer Research | / 14卷
关键词：
Progression Free Survival; Metastatic Breast Cancer; Circulate Tumor Cell; Serum Marker; Metastatic Breast Cancer Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Progression-free survival as a surrogate endpoint in advanced breast cancer
    Miksad, Rebecca A.
    Zietemann, Vera
    Gothe, Raffaella
    Schwarzer, Ruth
    Conrads-Frank, Annette
    Schnell-Inderst, Petra
    Stollenwerk, Bjoern
    Siebert, Uwe
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2008, 24 (04) : 371 - 383
  • [12] Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer
    Yang, Yunjie
    Liu, Zheng
    Wang, Qifeng
    Chang, Kun
    Zhang, Junyu
    Ye, Dingwei
    Kong, Yunyi
    Dai, Bo
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (05) : 383 - 389
  • [13] Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
    A. Migeotte
    V. Dufour
    A. van Maanen
    M. Berliere
    J. L. Canon
    D. Taylor
    F. P. Duhoux
    BMC Cancer, 21
  • [14] The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients
    Caglayan, Dilek
    Kocak, Mehmet Zahid
    Geredeli, Caglayan
    Atci, Muhammed Mustafa
    Tatli, Ali Murat
    Goksu, Sema Sezgin
    Eryilmaz, Melek Karakurt
    Araz, Murat
    Artac, Mehmet
    FUTURE ONCOLOGY, 2024, 20 (38) : 3099 - 3105
  • [15] The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer
    Fu, Fulbert
    Kano, Jessica
    Ma, Julia
    Guindy, Mera
    CURRENT ONCOLOGY, 2022, 29 (03) : 1761 - 1772
  • [16] Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
    Migeotte, A.
    Dufour, V
    van Maanen, A.
    Berliere, M.
    Canon, J. L.
    Taylor, D.
    Duhoux, F. P.
    BMC CANCER, 2021, 21 (01)
  • [17] The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
    Ziegler, Philipp
    Hartkopf, Andreas D.
    Wallwiener, Markus
    Haeberle, Lothar
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Ettl, Johannes
    Lueftner, Diana
    Mueller, Volkmar
    Michel, Laura L.
    Belleville, Erik
    Wimberger, Pauline
    Hielscher, Carsten
    Huebner, Hanna
    Uhrig, Sabrina
    Wurmthaler, Lena A.
    Hack, Carolin C.
    Mundhenke, Christoph
    Kurbacher, Christian
    Fasching, Peter A.
    Wuerstlein, Rachel
    Untch, Michael
    Janni, Wolfgang
    Taran, Florin-Andrei
    Lux, Michael P.
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Fehm, Tanja N.
    Schneeweiss, Andreas
    Goossens, Chloe
    BMC CANCER, 2024, 24 (01)
  • [18] Evaluating the Response of Palbociclib on Progression-Free Survival in Hormone Receptor-Positive Metastatic Breast Cancer
    Shikdar, Sufana
    Hall, Spencer
    Taylor, Brandon
    de los Angeles, Jennifer
    Tahirkheli, Mashal
    Zhao, Daniel
    Razaq, Wajeeha
    ONCOLOGY, 2022, 100 (06) : 337 - 343
  • [19] Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Tremblay, Gabriel
    BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 69 - 78
  • [20] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
12345